"Ophthalmic Solutions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS.
| Descriptor ID |
D009883
|
| MeSH Number(s) |
D26.776.708.645 D27.505.954.578.645 D27.720.752.608
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ophthalmic Solutions".
Below are MeSH descriptors whose meaning is more specific than "Ophthalmic Solutions".
This graph shows the total number of publications written about "Ophthalmic Solutions" by people in this website by year, and whether "Ophthalmic Solutions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 0 | 3 | 3 |
| 1997 | 1 | 3 | 4 |
| 1998 | 0 | 3 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 3 | 5 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 4 | 6 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ophthalmic Solutions" by people in Profiles.
-
Novel tactile bottle neck adaptor facilitates eye drop adherence in visually impaired patients. BMJ Open Ophthalmol. 2023 12 28; 8(1).
-
Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant. J Ocul Pharmacol Ther. 2023 07; 39(6):398-403.
-
Long term study of topical interferon a-2b eye drops as primary treatment of ocular surface squamous neoplasia. Ocul Surf. 2023 04; 28:108-114.
-
Clinical decision support malfunctions related to medication routes: a case series. J Am Med Inform Assoc. 2022 10 07; 29(11):1972-1975.
-
Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement. Am J Ophthalmol. 2022 09; 241:190-197.
-
A multicenter report of the use of plasma rich in growth factors (PRGF) for the treatment of patients with ocular surface diseases in North America. Ocul Surf. 2022 07; 25:40-48.
-
Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses. Ocul Surf. 2022 01; 23:162-168.
-
Rapamycin Eyedrops Increased CD4+Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface. Int J Mol Sci. 2020 Nov 24; 21(23).
-
Impact of Pupil Dilation on Optical Coherence Tomography Angiography Retinal Microvasculature in Healthy Eyes. J Glaucoma. 2020 11; 29(11):1025-1029.
-
Herpetic Eye Disease Study: A Controlled Trial of Topical Corticosteroids for Herpes Simplex Stromal Keratitis. Ophthalmology. 2020 04; 127(4S):S5-S18.